Ptc Therapeutics (PTCT) Interest Expenses (2012 - 2026)

Ptc Therapeutics' Interest Expenses history runs 15 years deep, the most recent figure standing at $155.4 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 202.79% year-over-year to $155.4 million in Q1 2026; TTM through Mar 2026 was $155.4 million, a 27.32% decrease from a year earlier, with the FY2025 full-year figure at $816.5 million, down 4.79% from the prior year.
• Interest Expenses slipped to $155.4 million in Q1 2026 per PTCT's latest filing, from $167.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $167.1 million in Q4 2025 and bottomed at -$4.3 million in Q4 2022.
• The 5-year median for Interest Expenses is $52.8 million (2022), against an average of $62.3 million.
• Across the five-year window, Interest Expenses sank 95.64% in 2022 and soared 572.79% in 2024, its largest moves.
• Year by year, Interest Expenses stood at -$4.3 million in 2022, then surged by 287.99% to $8.0 million in 2023, then surged by 572.79% to $54.1 million in 2024, then surged by 208.74% to $167.1 million in 2025, then retreated by 6.97% to $155.4 million in 2026.
• Per Business Quant, the three latest PTCT Interest Expenses figures stand at $155.4 million (Q1 2026), $167.1 million (Q4 2025), and $151.2 million (Q3 2025).